Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/106533
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bilbao Sieyro, Cristina | en_US |
dc.contributor.author | Rodríguez-Medina, Carlos | en_US |
dc.contributor.author | Florido, Yanira | en_US |
dc.contributor.author | Stuckey, Ruth | en_US |
dc.contributor.author | Sáez, María Nieves | en_US |
dc.contributor.author | Sánchez Sosa, José Santiago | en_US |
dc.contributor.author | González Martín, Jesús María | en_US |
dc.contributor.author | Santana, Guillermo | en_US |
dc.contributor.author | González-Pérez, Elena | en_US |
dc.contributor.author | Cruz-Cruz, Naylén | en_US |
dc.contributor.author | Fernández, Rosa | en_US |
dc.contributor.author | Molero Labarta, María Teresa | en_US |
dc.contributor.author | Gómez Casares, María Teresa | en_US |
dc.date.accessioned | 2021-04-06T13:34:41Z | - |
dc.date.available | 2021-04-06T13:34:41Z | - |
dc.date.issued | 2020 | en_US |
dc.identifier.issn | 2075-4418 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/106533 | - |
dc.description.abstract | Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remission (CR) and relapse (RL). Levels increased significantly at relapse (mean 1.07 PI/0.96 CR vs. 2.17 RL, p = 0.05/p = 0.03). In multivariate analysis, high BCL2-Dx were marginally associated with worse progression-free survival, while high PI levels or at CR had an independent negative impact on outcome (PI: HR 1.58, p = 0.014; CR: HR 1.96, p = 0.008). This behavior of high PI or CR BCL2 levels and increased risk was maintained in a homogeneous patient subgroup of age <70 and intermediate cytogenetic risk (PI: HR 2.44, p = 0.037; CR: HR 2.71, p = 0.049). Finally, for this subgroup, high BCL2 at relapse indicated worse overall survival (OS, HR 1.15, p = 0.05). In conclusion, high BCL2 levels PI or at CR had an independent negative impact on patient outcome. Therefore, BCL2 expression is a dynamic marker that may be useful during AML patient follow up, and BCL2 levels at PI and/or CR may influence response to anti-BCL2 therapy. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Diagnostics | en_US |
dc.source | Diagnostic [ ISSN 2075-4418], v. 10 (12), (Diciembre 2020) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 320101 Oncología | en_US |
dc.subject | Investigación | en_US |
dc.subject.other | Acute myeloid leukemia | en_US |
dc.subject.other | BCL2 inhibitors | en_US |
dc.subject.other | Biomarkers | en_US |
dc.subject.other | Patient outcome | en_US |
dc.subject.other | Induction therapy | en_US |
dc.subject.other | Molecular diagnostics | en_US |
dc.title | BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.identifier.doi | 10.3390/diagnostics10121048 | en_US |
dc.identifier.issue | 12 | - |
dc.relation.volume | 10 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 8 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Diciembre 2020 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 0,622 | |
dc.description.jcr | 3,706 | |
dc.description.sjrq | Q3 | |
dc.description.jcrq | Q2 | |
dc.description.scie | SCIE | |
item.fulltext | Con texto completo | - |
item.grantfulltext | open | - |
crisitem.author.dept | Departamento de Morfología | - |
crisitem.author.dept | Departamento de Didácticas Específicas | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-4796-1445 | - |
crisitem.author.orcid | 0000-0002-7211-8003 | - |
crisitem.author.orcid | 0000-0003-0505-5126 | - |
crisitem.author.fullName | Bilbao Sieyro, Cristina | - |
crisitem.author.fullName | Sánchez Sosa, José Santiago | - |
crisitem.author.fullName | Molero Labarta, María Teresa | - |
crisitem.author.fullName | Gómez Casares, María Teresa | - |
Appears in Collections: | Artículos |
WEB OF SCIENCETM
Citations
5
checked on Mar 30, 2025
Page view(s)
109
checked on Feb 3, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.